Diagnostic and prognostic implications of family history of fibrotic interstitial lung diseases Authors: D. Duminy-Luppi, A. Alcaide-Aldeano, L. Planas-Cerezales, G. Bermudo, V. Vicens-Zygmunt, P. Luburich, B. Del Río-Carrero, R. Llatjós, L. Pijuan, I. Escobar, F. Rivas, A. Montes-Worboys, Y. Gutiérrez-Rodríguez, D. Rodríguez-Plaza, A. Padró-Miquel, A. Esteve-Garcia, B. Fernández-Varas, C. Flores, M. Fuentes, J. Dorca, S. Santos, R. Perona, A. Günther, J. Shull, M. Molina-Molina Published: 2024 ABSTRACT BackgroundPatients with familial fibrotic interstitial lung disease (ILD) experience worse survival than patients with sporadic disease. Current guidelines do not consider family aggregation or genetic information in the diagnostic algorithm for idiopathic pulmonary fibrosis or other fibrotic ILDs. Better characterizing familial cases could help in diagnostic and treatment decision-making.MethodsThis retrospective cohort study included 222 patients with fibrotic ILD (104 familial and 118 sporadic) from Bellvitge University Hospital. Clinical, radiological, pulmonary functional tests (PFT), and histological evaluations were performed at diagnosis and follow-up. Telomere shortening and disease-associated variants (DAVs) in telomerase-related genes were analysed in familial patients and sporadic patients with telomeric clinical signs. Primary outcomes were the presence of a UIP histological pattern and disease progression.ResultsPatients with idiopathic pulmonary fibrosis (IPF) (52%), fibrotic hypersensitivity pneumonitis (23%), and other fibrotic ILDs (25%) were included. 42% of patients underwent lung biopsy. Patients with family aggregation were younger and less frequently associated comorbidities, male sex, and smoking history. However, usual interstitial pneumonia (UIP) was more frequent on pathology (p = 0.005; OR 3.37), especially in patients with indeterminate or non-UIP radiological patterns. Despite similar PFT results at diagnosis, familial patients were more likely to present with progressive disease (p = 0.001; OR 3.75). Carrying a DAV increased the risk of fibrotic progression in familial and sporadic patients (p = 0.029, OR 5.01).DiscussionFamilial patients diagnosed with different fibrotic ILDs were more likely to exhibit a histological UIP pattern and disease progression than sporadic patients, independent of radiological findings and pulmonary function at diagnosis.ConclusionConsidering the diagnostic likelihood of the histological UIP pattern and disease outcome, the presence of family aggregation would be useful in the decision making of multidisciplinary committees.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12931-024-03063-y. Background Fibrotic interstitial lung diseases (ILDs) represent a substantial burden, with a prevalence of 76 cases per 100,000 inhabitants in Europe. These include drug or radiation-induced fibrotic ILDs, inhaled exposure-related fibrotic ILDs (organic or inorganic substances), autoimmune or connective tissue disease(CTD)-associated fibrotic ILDs and idiopathic interstitial pneumonias (IIPs) [idiopathic nonspecific interstitial pneumonia (NSIP) and idiopathic pulmonary fibrosis (IPF)], among others [1]. IPF is the most lethal and frequent fibrotic IIP, with an estimated mean prevalence of 2–10 cases per 100,000 inhabitants [2, 3]. Pulmonary fibrosis is present in many other non-IPF ILDs and may progress despite conventional integral treatment, which is defined as progressive pulmonary fibrosis (PPF) [4–6]. The incidence of PPF in non-IPF patients varies between 13 and 40%, depending on the entity [1, 7]. Pirfenidone and Nintedanib, anti-fibrotic drugs evaluated in clinical trials, have shown to slow functional decline and disease progression [6–10]. Lung transplantation improves survival in eligible patients with PPF [6, 11]. A confident diagnosis has strong implications for patient management and prognosis [12]. The multidisciplinary ILD diagnostic approach includes clinical, functional, radiological and serological assessments, with or without bronchoscopy or surgical lung sampling [1]. In IPF, lung biopsy is not required for patients with radiological consistent or probable UIP patterns on high resolution computed tomography (HRCT) and proper clinical context; due to the high probability (> 90%) of a histological UIP pattern being found in lung biopsy [6, 13, 14]. Therefore, lung biopsy is mostly indicated in young patients with fibrotic ILDs and those with indeterminate UIP or non-UIP radiological patterns, balancing the potential morbidity and mortality of the procedure [6]. Familial pulmonary fibrosis (FPF) is defined as the presence of at least 2 cases of pulmonary fibrosis in the same family [15, 16]. Familial aggregation is the most important risk factor for IPF, and is also associated with earlier onset of the disease [17]. Up to 20% of patients with IPF have a first degree relative with ILD [18]. Family history also predicts worse transplant-free survival and an increased risk of death, both in IPF and non-IPF fibrotic ILD patients [19, 20]. Furthermore, disease-associated variants in telomere-related genes (TRGs) are detected in approximately 30% of the families (TERT, TERC, DKC1, PARN, RTEL1, etc.) [21]. Telomere attrition, a consequence of TRG pathogenic variants, may be found in sporadic and familial fibrotic ILD. IPF patients with telomere shortening more frequently exhibit a decrease in forced vital capacity (FVC) and short transplant-free survival [22]. Similar results have been reported for other non-IPF fibrotic ILDs with telomere shortening such as hypersensitivity pneumonitis, unclassifiable ILD, interstitial pneumonitis with autoimmune features (IPAF) and CTD-ILD [23, 24]. Genetic factors of FPF have already been extensively described [16, 25]. Despite increasing evidence of the impact of family history and the genetic component of the disease, recommendations for clinical practice diagnosis are just starting to emerge. These issues are only discussed in the most recent guidelines as future directions to improve patient diagnosis and management [6, 26]. To assist in the differential diagnosis of fibrotic ILDs; and in the management and prognosis prediction of patients, we aimed to evaluate the relevance of familial aggregation and telomere dysfunction in predicting the UIP histological pattern and progressive fibrotic disease. Methods The primary outcomes were the presence of a UIP histopathological pattern and progressive fibrotic disease. This retrospective observational study included 222 consecutive newly diagnosed patients with fibrotic ILD at the ILD Unit of Bellvitge University Hospital (HUB), in L’Hospitalet de Llobregat, from January 2015 to December 2019. An ILD was considered fibrotic when presented with features of diffuse fibrosing lung disease of > 10% extent on an HRCT scan [27]. ILD diagnoses and classifications were made according to the most recent IPF and ILD guidelines [6, 15, 28]. Four patients were excluded because of a non-ILD diagnosis. The Ethics Committee of HUB approved the study (PR307/16), and all patients provided written informed consent before inclusion, including written informed consent for genetic testing if needed. Clinical data were recorded at the time of patient inclusion. Patients were split into sporadic and familial groups depending on the existence of at least 2 cases of fibrotic ILD in the same family, resulting in 118 patients in the sporadic group and 104 patients in the familial group [15, 18]. A flow chart of the study cohort composition is available in Fig. 1. Fig. 1Flow chart of grouping based on final diagnosisIPF: idiopathic pulmonary fibrosis, fHP: fibrotic hypersensitivity pneumonitis, uILD: unclassifiable interstitial lung disease, CPFE: combined pulmonary fibrosis and emphysema, SRIF: smoking-related interstitial fibrosis, CTD-ILD: connective tissue disease associated interstitial lung disease. Other include ANCA-associated vasculitis, cocaine-induced pulmonary fibrosis, stage IV sarcoidosis, fibrotic non-specific interstitial pneumonia, radiotherapy induced pulmonary-fibrosis, interstitial pneumonia with autoimmune features and pleuroparenchymal fibroelastosis Flow chart of grouping based on final diagnosis IPF: idiopathic pulmonary fibrosis, fHP: fibrotic hypersensitivity pneumonitis, uILD: unclassifiable interstitial lung disease, CPFE: combined pulmonary fibrosis and emphysema, SRIF: smoking-related interstitial fibrosis, CTD-ILD: connective tissue disease associated interstitial lung disease. Other include ANCA-associated vasculitis, cocaine-induced pulmonary fibrosis, stage IV sarcoidosis, fibrotic non-specific interstitial pneumonia, radiotherapy induced pulmonary-fibrosis, interstitial pneumonia with autoimmune features and pleuroparenchymal fibroelastosis Clinical features, including extrapulmonary manifestations of telomere shortening and family history, were recorded [29, 30]. Pulmonary function test (PFT) results were collected and both the FVC and hemoglobin-adjusted diffusing capacity for carbon monoxide (DLCO) were collected at diagnosis and annually during follow-up. Changes were evaluated based on the values at diagnosis and one year after diagnosis. Radiologic fibrotic signs were visually semiquantified by two independent expert radiologists, who compared the diagnostic HRCT with a second HRCT (obtained 24 months after diagnosis or closest available). The need for transplantation or death at any point in follow-up was noted, and an extensive case review was performed. Lung biopsy was performed when required for a final diagnosis based on ATS/ERS guidelines or multidisciplinary committee consensus, through transbronchial cryobiopsy or video-assisted thoracic surgery (VATS). HRCT and histopathological pattern definitions were reviewed by the multidisciplinary committee at the time of diagnosis, according to the IPF guidelines in place [15, 28, 31]. Fibrotic progression was considered when the FVC decline was ≥ 10% of the predicted value (without any other explanation) 1 year after the diagnosis or an increase in the extent of chest HRCT fibrotic signs on the follow-up HRCT, the need for a lung transplant or death due to respiratory disease [4, 5, 8, 32]. DNA samples were isolated from mouth epithelial cells and peripheral blood mononuclear cells with commercial kits (Isohelix, Cell Projects Ltd) as previously described [22]. Telomere length was assessed first by quantitative polymerase chain reaction (qPCR) and, when needed, by Southern blot analysis of terminal restriction fragment lengths (TRFLs) [22]. The ratio of telomere repeat copy number to that of the single-copy gene 36B4 was determined and compared with that of a reference DNA sample. Age-adjustment was made by calculating the z-score as previously described [22]. A telomere shortening was defined by a z-score < 25th percentile, and severe telomere shortening was considered when it was < 10th percentile. TRG sequence variants were identified by panel sequencing or whole-exome sequencing in patients without any identified variant of interest and high suspicion of a genetic cause (strong family aggregation and inheritance or clear clinical conditions associated with telomere dysfunction and severe telomere attrition). The whole-exome sequencing procedure was conducted as described previously [33]. Relevant genetic variants, designated disease-associated variants (DAVs), encompassed those classified as pathogenic, likely pathogenic or variants of uncertain significance possibly associated with diseases identified in the TERT, TERC, PARN, DKC1 or RTEL1 genes [34, 35]. A summary of the relevant collected variables was completed with basic descriptive statistics, using either proportions for qualitative variables or the arithmetic mean and standard deviation for quantitative variables, calculated for overall, the familial group and the sporadic group. P values of differences between these categories for quantitative variables were calculated using independent samples t-test (or paired sample t-test) if both assumptions of homogeneity of variances (with Levene’s test) and normality (Shapiro-Wilk test, and Q-Q plot) were met. Otherwise, Mann-Whitney U test was employed for independent samples. For differences in proportions, the independent samples chi-square test of association was used, unless expected frequencies in at least one level of the variable were less than 5, for which Fisher’s exact test was used. A binomial logistic regression model was built to adjust for potential confounding among three primary variables of interest, which showed significant statistical differences in the univariate analysis. A computed binary categorical variable, “progressive disease”, was created to match the definition of fibrotic progression previously described. The pattern on biopsy was simplified into a binary categorical variable, regrouping “consistent UIP” and “probable UIP” into “UIP” and others into “non-UIP” [6]. For the binomial logistic regression model, telomere shortening was transformed into a binary categorical variable, with a 25% cut-off, since telomere length < 10th percentile is usually associated with the presence of disease-associated TRG variants (pathogenic, probably pathogenic, or uncertain significance favouring pathogenicity), but some of them are not associated with severe shortening [25]. P values < 0.05 were regarded as statistically significant. The magnitude of the difference in proportions was provided as odds ratios (ORs) and 95% confidence intervals (CIs). Results A summary of patient characteristics is available in Table 1. Familial patients were younger (p < 0.001) and presented fewer comorbidities and smoking history (p < 0.001). Despite a male sex predominance in both groups, the female frequency was higher among familial cases (p = 0.037). A significantly greater percentage of sporadic had probable or confident UIP radiological patterns (p < 0.001). Familial patients were more likely to have telomere shortening (p < 0.001), extrapulmonary disease manifestations (p < 0.001), blood count abnormalities at diagnosis (p < 0.001), liver abnormalities (p < 0.001), to require a multidisciplinary committee diagnostic approach (p = 0.025) and to carry a disease-associated TRG variant (p < 0.001). There were no significant differences in the occurrence of lung cancer or other cancers. The FVC and DLCO at diagnosis, as well as the proportion of patients who received antifibrotic drugs or prednisone, were similar. More IPF patients were included in the sporadic group (p < 0.001). Most sporadic IPF patients (88.6%) exhibited a probable or consistent UIP HRCT pattern, while only 38.6% of familial IPF patients exhibited this pattern. Patients who experienced worsening of radiological fibrosis after two years were more likely to be in the familial group (OR 3.41, 95% CI 1.86–6.24; p < 0.001). Table 1Baseline characteristics of patientsOveralln = 222Familialn = 104Sporadicn = 118P value Age at diagnosis (years) 66.5 ± 10.063.2 ± 11.269.4 ± 7.9< 0.001u Gender (Female) 62 (28)36 (35)26 (22)0.037χ Comorbidities (Yes) 164 (74)60 (58)104 (88)< 0.001χ Smoking history (Yes) 130 (59)47 (45)83 (70)< 0.001χ Antifibrotic drugs (Yes) 130 (59)60 (58)70 (59)0.806χ Prednisone (Yes) 80 (36)43 (41)37 (31)0.122χ Idiopathic pulmonary fibrosis 122 (55)44 (42)78 (66)< 0.001χ Radiological Pattern n = 221 n = 104 n = 117 < 0.001χ Non-UIP86 (39)52 (50)34 (29) Indeterminate UIP27 (12)21 (20)6 (5) Probable UIP63 (29)12 (12)51 (44) UIP45 (20)19 (18)26 (22) Relative Telomere Length n = 149 n = 102 n = 47 - p75-p1001 (1)1 (1)0 (0) p50-7518 (12)13 (13)5 (11) p25-5045 (30)18 (18)27 (57)